FP
CRSP icon

Financial Perspectives’s CRISPR Therapeutics CRSP Stock Holding History

Financial Perspectives’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Hold
2,422
– – 0.03% 218
2026
Q1 		$115K Hold
2,422
– – 0.03% 223
2025
Q4 		$127K Hold
2,422
– – 0.03% 207
2025
Q3 		$157K Hold
2,422
– – 0.04% 184
2025
Q2 		$118K Buy
2,422
+13
+0.5% +$503 0.04% 209
2025
Q1 		$82.4K Sell
2,409
-13
-0.5% -$551 0.03% 237
2024
Q4 		$95.3K Hold
2,422
– – 0.03% 225
2024
Q3 		$114K Hold
2,422
– – 0.04% 201
2024
Q2 		$131K Hold
2,422
– – 0.05% 173
2024
Q1 		$165K Buy
2,422
+120
+5% +$8.59K 0.06% 152
2023
Q4 		$144K Hold
2,302
– – 0.06% 164
2023
Q3 		$104K Hold
2,302
– – 0.05% 180
2023
Q2 		$129K Buy
2,302
+441
+24% +$25K 0.06% 159
2023
Q1 		$84.2K Hold
1,861
– – 0.04% 210
2022
Q4 		$75.7K Sell
1,861
-63
-3% -$3.34K 0.04% 208
2022
Q3 		$126K Buy
1,924
+149
+8% +$10.8K 0.07% 152
2022
Q2 		$108K Hold
1,775
– – 0.06% 165
2022
Q1 		$111K Buy
1,775
+80
+5% +$5.02K 0.05% 178
2021
Q4 		$128K Sell
1,695
-1,510
-47% -$132K 0.06% 154
2021
Q3 		$359K Sell
3,205
-51
-2% -$6.41K 0.18% 80
2021
Q2 		$527K Buy
3,256
+201
+7% +$24.4K 0.26% 65
2021
Q1 		$372K Buy
3,055
+1,268
+71% +$191K 0.2% 80
2020
Q4 		$274K Buy
1,787
+894
+100% +$106K 0.16% 92
2020
Q3 		$74.7K Buy
893
+589
+194% +$52.2K 0.05% 165
2020
Q2 		$22.3K Hold
304
– – 0.02% 259
2020
Q1 		$12.9K Hold
304
– – 0.01% 294
2019
Q4 		$18.5K Buy
+304
New +$16.6K 0.01% 267

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Financial Perspectives's CRSP Position: Q2 2026 in Review

Financial Perspectives held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 2,422 shares worth $132K. The position accounts for 0.03% of the portfolio, ranked #218.

Financial Perspectives first reported a position in CRSP in Q4 2019 and has held it in 27 quarters since. The position peaked at $527K in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Financial Perspectives held 2,422 shares of CRISPR Therapeutics worth $132K as of Q2 2026.
  • Financial Perspectives left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.03% of Financial Perspectives's portfolio in Q2 2026, its #218 holding.
  • Financial Perspectives first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Financial Perspectives's CRISPR Therapeutics position peaked at $527K in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Financial Perspectives's 13F filing for Q2 2026, filed 24 Jul 2026.